AltMountain

Ishara Investments LP

Los Angeles, CA · CRD 331869
Hedge fund manager

Ishara Investments LP is an SEC-registered investment adviser based in Los Angeles, CA that reports managing 1 hedge fund on Form ADV. It reports $259.1 million in regulatory assets under management. Its private funds, of all types, hold $19.9 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +22.9% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +22.9% from Q1 2026 to Q2 2026, compared with +9.5% for the S&P 500, based on 13F filings.

Regulatory assets under management
$259.1 millionForm ADV Item 5.F
Gross assets of private funds
$19.9 millionAll private fund types, Form ADV
Hedge funds managed
11 private funds in total
Employees
6Form ADV Item 5.A
Registration
SEC-registered adviserCRD 331869
Latest Form ADV
03/19/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+22.9%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 quarters+22.9%Q1 2026 – Q2 2026
S&P 500+9.5%Same quarters, price only
13F holdings$136.1 million41 positions, 2026-06-30
$95$109$123Q1 2026Q2 202613F est. $123S&P 500 $110
QuarterEst. 13F returnS&P 500
Q2 2026+20.8%+14.8%
Q1 2026+1.7%-4.6%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 40 share positions ($119,503,810) reported by Ishara Investments LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Travere Therapeutics Inc7.14%
  • Cytokinetics Inc7.06%
  • Bridgebio Pharma Inc5.51%
  • Acadia Pharmaceuticals Inc5.40%
  • Tarsus Pharmaceuticals Inc4.60%
  • PTC Therapeutics Inc4.34%
  • Praxis Precision Medicines I4.14%
  • Vera Therapeutics Inc4.05%
  • Arcutis Biotherapeutics Inc3.98%
  • Annexon Inc3.96%
StockValue% of 13F portfolioSharesShares vs prior quarter
Travere Therapeutics Inc$8,537,6007.14%145,000+76.83%
Cytokinetics Inc$8,436,4807.06%128,000+290.24%
Bridgebio Pharma Inc$6,580,0005.51%100,000+74.22%
Acadia Pharmaceuticals Inc$6,448,0005.40%320,000-21.95%
Tarsus Pharmaceuticals Inc$5,502,7004.60%70,000New
PTC Therapeutics Inc$5,182,4004.34%80,000New
Praxis Precision Medicines I$4,950,9104.14%17,000-24.61%
Vera Therapeutics Inc$4,843,5004.05%150,000+1,363.41%
Arcutis Biotherapeutics Inc$4,757,4003.98%180,000New
Annexon Inc$4,737,6003.96%1,120,000+36.59%
United Therapeutics Corp Del$4,335,1203.63%8,000New
Newamsterdam Pharma Company$3,891,2003.26%160,000+333.60%
Xeris Biopharma Holdings Inc$3,824,0003.20%400,000-67.48%
Celcuity Inc$3,816,9603.19%48,000New
DBV Technologies S A$3,175,2002.66%270,000+46.34%
Viridian Therapeutics Inc$3,088,5002.58%150,000New
Zentalis Pharmaceuticals Inc$2,991,6002.50%1,080,000+5.37%
Biomarin Pharmaceutical Inc$2,880,0002.41%48,000-66.55%
Biogen Inc$2,710,5602.27%12,000New
Mineralys Therapeutics Inc$2,513,0002.10%100,000-2.44%
Ligand Pharmaceuticals Inc$2,498,9602.09%8,000New
Ultragenyx Pharmaceutical In$2,404,8002.01%160,000-21.95%
Vaxcyte Inc$2,276,0001.90%40,000-51.22%
Oric Pharmaceuticals Inc$2,155,2001.80%160,000+30.08%
Axsome Therapeutics Inc.$1,843,9001.54%10,000-39.02%
Silence Therapeutics PLC$1,748,8001.46%160,000-3.64%
Beam Therapeutics Inc$1,711,5001.43%70,000+70.73%
Biohaven LTD$1,602,0001.34%120,000New
Contineum Therapeutics Inc$1,449,3601.21%108,000-47.32%
Genmab A/s$1,427,0001.19%40,000-60.98%
Neurocrine Biosciences Inc$1,134,7200.95%8,000New
Monopar Therapeutics Inc$956,0400.80%12,000-2.44%
Moonlake Immunotherapeutics$936,0000.78%80,000New
Ars Pharmaceuticals Inc$862,0000.72%200,000-7.08%
Ionis Pharmaceuticals Inc$714,4000.60%16,000New
Olema Pharmaceuticals Inc$691,2000.58%80,000New
Lexicon Pharmaceuticals Inc$600,0000.50%320,000-74.82%
Wave Life Sciences Inc.$592,0000.50%160,000New
Savara Inc$412,8000.35%80,000New
Gossamer Bio Inc$284,4000.24%24,000New

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 16 new positions, 17 sold out, 10 increased, 14 reduced and 0 unchanged.

Number of positions (a count, not dollars)

  • New positions16
  • Increased10
  • Unchanged0
  • Reduced14
  • Sold out17

New positions

StockValueShares
Tarsus Pharmaceuticals Inc$5,502,70070,000
PTC Therapeutics Inc$5,182,40080,000
Arcutis Biotherapeutics Inc$4,757,400180,000
United Therapeutics Corp Del$4,335,1208,000
Celcuity Inc$3,816,96048,000
Viridian Therapeutics Inc$3,088,500150,000
Biogen Inc$2,710,56012,000
Ligand Pharmaceuticals Inc$2,498,9608,000
Biohaven LTD$1,602,000120,000
Neurocrine Biosciences Inc$1,134,7208,000
Moonlake Immunotherapeutics$936,00080,000
Ionis Pharmaceuticals Inc$714,40016,000
Olema Pharmaceuticals Inc$691,20080,000
Wave Life Sciences Inc.$592,000160,000
Savara Inc$412,80080,000
Gossamer Bio Inc$284,40024,000

Sold out

StockValue at Jun 30, 2026Shares held then
Agios Pharmaceuticals Inc$6,086,040164,000
Insmed Inc$5,464,27551,250
Crinetics Pharmaceuticals In$5,369,770143,500
Tonix Pharmaceuticals Hldg C$4,316,070338,250
Kura Oncology Inc$3,035,948276,750
Nuvation Bio Inc$2,095,920369,000
Wave Life Sciences LTD$1,905,680328,000
Nektar Therapeutics$1,860,43726,650
Scholar Rock Hldg Corp$1,691,25030,750
Enliven Therapeutics Inc$1,664,60032,800
Alnylam Pharmaceuticals Inc$1,542,7795,125
Sionna Therapeutics Inc$1,350,540123,000
Vertex Pharmaceuticals Inc$1,221,9562,460
Erasca Inc$751,12041,000
Immatics N.V$311,49830,750
Mereo Biopharma Group PLC$244,232768,750
Gossamer Bio Inc$134,972820,000

Largest increases

StockChange in sharesChangeValue nowShares now
Cytokinetics Inc+95,200+290.24%$8,436,480128,000
Vera Therapeutics Inc+139,750+1,363.41%$4,843,500150,000
Travere Therapeutics Inc+63,000+76.83%$8,537,600145,000
Newamsterdam Pharma Company+123,100+333.60%$3,891,200160,000
Bridgebio Pharma Inc+42,600+74.22%$6,580,000100,000
Annexon Inc+300,000+36.59%$4,737,6001,120,000
DBV Technologies S A+85,500+46.34%$3,175,200270,000
Beam Therapeutics Inc+29,000+70.73%$1,711,50070,000
Oric Pharmaceuticals Inc+37,000+30.08%$2,155,200160,000
Zentalis Pharmaceuticals Inc+55,000+5.37%$2,991,6001,080,000

Largest reductions

StockChange in sharesChangeValue nowShares now
Xeris Biopharma Holdings Inc-830,000-67.48%$3,824,000400,000
Biomarin Pharmaceutical Inc-95,500-66.55%$2,880,00048,000
Vaxcyte Inc-42,000-51.22%$2,276,00040,000
Genmab A/s-62,500-60.98%$1,427,00040,000
Acadia Pharmaceuticals Inc-90,000-21.95%$6,448,000320,000
Lexicon Pharmaceuticals Inc-951,000-74.82%$600,000320,000
Praxis Precision Medicines I-5,550-24.61%$4,950,91017,000
Contineum Therapeutics Inc-97,000-47.32%$1,449,360108,000
Axsome Therapeutics Inc.-6,400-39.02%$1,843,90010,000
Ultragenyx Pharmaceutical In-45,000-21.95%$2,404,800160,000
Silence Therapeutics PLC-6,050-3.64%$1,748,800160,000
Ars Pharmaceuticals Inc-15,235-7.08%$862,000200,000
Mineralys Therapeutics Inc-2,500-2.44%$2,513,000100,000
Monopar Therapeutics Inc-300-2.44%$956,04012,000

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Hedge funds filing Form D (1)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌​‌⁠